Advertisement

Topics

Bristol-Myers Squibb and TARIS Biomedical LLC Company Profile

02:32 EDT 18th August 2018 | BioPortfolio

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat bladder diseases. We are advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed. www.tarisbiomedical.com


News Articles [882 Associated News Articles listed on BioPortfolio]

Bristol-Myers Squibb And Nektar To Collaborate On Immuno-Oncology Program

NewsUnder the collaboration, Bristol-Myers Squibb will pay Nektar Therapeutics $1.85 billion upfront. The companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Sq...

Weekly Analysts' Ratings Updates for Bristol-Myers Squibb

Several brokerages have updated their recommendations and price targets on shares of Bristol-Myers Squibb in the last few weeks: 2/16/2018 - Bristol-Myers Squibb was given a new $78.00 price target on...

Bristol-Myers Squibb and Flatiron to collaborate on RWE

Bristol-Myers Squibb and Flatiron have expanded their relationship by announcing a three-year collaboration agreement focused on the use of real...Read More... The post Bristol-Myers Squibb and Flatir...

Brokers Offer Predictions for Bristol-Myers Squibb Co's Q3 2018 Earnings

Bristol-Myers Squibb Co - Investment analysts at William Blair dropped their Q3 2018 EPS estimates for Bristol-Myers Squibb in a report released on Wednesday. William Blair analyst M. Phipps now expec...

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combi...

Bristol-Myers Squibb (BMY) Expected to Announce Quarterly Sales of $5.38 Billion

Brokerages forecast that Bristol-Myers Squibb will post $5.38 billion in sales for the current fiscal quarter, according to Zacks Investment Research . Four analysts have made estimates for Bristol-My...

Bristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.10 Billion

Wall Street analysts forecast that Bristol-Myers Squibb will post $5.10 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Bristol-Myers Squibb'...

Bristol-Myers Squibb to Take Part in Barclays Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Global Healthcare Conference on Wednesday, March 14, 2018, in Miami. Murdo Gordon, executive vice presiden...

PubMed Articles [426 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.

Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous paracetamol has been widely used to treat moderate postoperative pain. Surgery is the main method of treatme...

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.

Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical ...

The role of biomaterials in overcoming barriers to regeneration in the central nervous system.

In Reply to Wang and Myers.

Clinical Trials [178 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Safety and Tolerability Study of the Taris Placebo System

The aim of this protocol is to evaluate the tolerability of the Taris placebo system for the development program and to provide key safety and tolerability data for the Taris platform.

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Companies [722 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Bristol-Myers Squibb and TARIS Biomedical LLC

TARIS Biomedical® is building a unique therapeutically-focused urology company, developing targeted new therapies for millions of patients suffering from difficult-to-treat ...

More Information about "Bristol-Myers Squibb and TARIS Biomedical LLC" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb and TARIS Biomedical LLC news stories on BioPortfolio along with dozens of Bristol-Myers Squibb and TARIS Biomedical LLC Clinical Trials and PubMed Articles about Bristol-Myers Squibb and TARIS Biomedical LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb and TARIS Biomedical LLC Companies in our database. You can also find out about relevant Bristol-Myers Squibb and TARIS Biomedical LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record